
Decoy Therapeutics fell 91.8% from $11.03 to $0.90, behind the S&P 500's +11.2%. Its worst day was Jan 14 (−30.4%), and its low came Nov 16 at $0.90.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Decoy Therapeutics closed at its highest level of the year, 36.0% above where the year started.
+53.4% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
Decoy Therapeutics shares rose 25.8%, while the S&P 500 rose 1.9%.
+25.8% · S&P 500 +1.9%
EPS of $-129.10 missed the $-12.96 estimate on $0.00 revenue.
−3.2% · S&P 500 +0.8%
EPS of $-4.18 missed the $-4.08 estimate on $0.00 revenue.
−4.9% · S&P 500 +0.2%
Decoy Therapeutics shares rose 62.3%, while the S&P 500 rose 1.6%.
+62.3%, the year's best day · S&P 500 +1.6%
Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.
−25.8% · S&P 500 0.0%
EPS of $-4.46 missed the $-2.88 estimate on $227,629.00 revenue.
−5.0% · S&P 500 +0.7%
Decoy Therapeutics shares fell 25.2%, while the S&P 500 fell 0.7%.
−25.2% · S&P 500 −0.7%
EPS of $-3.53 missed the $-2.59 estimate on $307,430.00 revenue.
−7.1% · S&P 500 −0.4%
Where it ended: a close of $0.90 on Nov 16, 2026.
Nothing in the past 12 months.
All DCOY dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DCOY and SPY from Benzinga historical bars. Not investment advice.